arrow
M

Martin Pichler

university of augsburg
H-index:69
Citation Count:1.6万
Views:0

Biography

No content for now.

Education

No content for now.

Work Experience

No content for now.

Honors & Awards

No content for now.

Clinical Significance and Therapeutic Potential of Long Non-Coding RNA H19 in Soft Tissue Sarcoma

长链非编码RNA H19在软组织肉瘤中的临床意义和治疗潜力

2026-01-110
OAAI
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis

恩福妥单抗 vedotin 联合帕博利珠单抗治疗初治转移性尿路上皮癌患者:一项奥地利真实世界分析

2025-10-220
OAAI
FGFR1/3 Signaling as an Achilles’ Heel of Phenotypic Diversity in Urothelial Carcinoma

FGFR1/3信号作为尿路上皮癌表型多样性的阿喀琉斯之踵

2025-07-280
OAAI
Arterial thromboembolic events in testicular cancer patients: short- and long-term incidence, risk factors, and impact on mortality

睾丸癌患者的动脉血栓栓塞事件:短期与长期发生率、危险因素及对死亡率的影响

2025-02-140
OAAI
Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer
2024-11-170
OAAI
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study

顺铂耐药性生殖细胞肿瘤患者的特点与姑息管理:全球生殖细胞癌协作组(G3)回顾性登记研究

2024-09-010
PRE
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
2024-08-192
OAAI
Assessing the role and impact of research in clinical practice among acupuncturists in western countries: a multinational cross-sectional survey
2024-07-310
OAAI
Enhancing oncogenic signaling to kill cancer cells

增强致癌信号杀死癌细胞

2024-06-010
OAAI
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework

癌症治疗的ERK通路激动: 证据、见解和目标发现框架

2024-03-1410
OAAI
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

免疫肿瘤学联合治疗的晚期肾细胞癌和中度或低风险国际转移性肾细胞癌数据库联盟标准患者的真实世界结果: 风险组的差异有效性?

2024-02-0118
PRE
MiR-4646-5p Acts as a Tumor-Suppressive Factor in Triple Negative Breast Cancer and Targets the Cholesterol Transport Protein GRAMD1B

MiR-4646-5p在三阴性乳腺癌中作为肿瘤抑制因子并靶向胆固醇转运蛋白GRAMD1B

2023-12-261
OAAI
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study
2023-12-144
OAAI
Prognostic Significance of Pathological Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
2023-10-270
PRE
Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
2023-10-102
OAAI
MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib
2023-10-066
OAAI
Efficacy of a tailored approach with nivolumab (N) and nivolumab plus ipilimumab (N plus I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
2023-10-010
OAAI
Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
2023-10-010
OA